Hashii Yoshiko, Kusafuka Takeshi, Ohta Hideaki, Yoneda Akihiro, Osugi Yuko, Kobayashi Yasutsugu, Fukuzawa Masahiro, Hara Junichi
Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Pediatr Hematol Oncol. 2008 Jun;25(5):439-50. doi: 10.1080/08880010802104601.
The aim of this study was to clarify the feasibility of a novel treatment strategy consisting of postponed primary surgery till the end of systemic chemotherapy including HDC without interruption by local therapy for neuroblastoma patients at a high risk for relapse. After induction chemotherapy, patients received double conditioning HDC consisting of thiotepa and melphalan. Radical surgery was applied to local lesions. Irradiation was not applied to any lesions. Eleven consecutive pediatric neuroblastoma patients were treated according to this strategy. Seven of 11 patients remained in complete remission for 21-171 months. This treatment strategy seems feasible and a further study is warranted.
本研究的目的是阐明一种新的治疗策略的可行性，该策略包括将原发性手术推迟至全身化疗结束，包括大剂量化疗（HDC），在此期间不进行局部治疗，用于复发风险高的神经母细胞瘤患者。诱导化疗后，患者接受由噻替派和美法仑组成的双重预处理大剂量化疗。对局部病变进行根治性手术。不对任何病变进行放疗。11例连续的儿童神经母细胞瘤患者按照该策略进行治疗。11例患者中有7例持续完全缓解21至171个月。这种治疗策略似乎可行，值得进一步研究。
